ClinicalTrials.gg
RecruitingNCT07811765Updated Sep 17, 2026

Preconception vs First-Trimester Screening and Treatment for Iron Deficiency Anemia

An interventional study of Preconception Anemia Screening and Treatment Strategy and Early-Pregnancy Anemia Screening and Treatment Strategy in Iron Deficiency Anemia, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This cluster randomized trial compares preconception with early-pregnancy anemia screening and iron supplementation, assessing late pregnancy iron deficiency anemia and maternal and infant outcomes.

02

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Anemia Intervention Timing
  • Preconception
  • First Trimester
  • Iron Deficiency Anemia
  • Randomized Controlled Trial
03

In context

Anemia, Iron-Deficiency

600 studies on the registry are indexed under Anemia, Iron-Deficiency; 95 are open to participants now.

This study's planned enrollment of 960 is above the median of 100 across 459 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-45 years
  • Residence in a participating township
  • Intention to attempt natural conception within 6 months after enrollment
  • Ability to complete the required study procedures
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • 1.Non-iron deficiency anemia or other hematologic disorders: thalassemia, sickle cell anemia, anemia of chronic disease, and other hematologic conditions will be excluded based on complete blood count findings (including concentration) in combination with questionnaire assessment. Renal insufficiency ( \<45 mL/min/1.73 m²)

    2: hepatic insufficiency ( or AST >3 times the )

    3: uncontrolled heart disease ( [NYHA] functional class III-IV) Acute or chronic infections, including infection, active tuberculosis, and uncontrolled Multiple pregnancy

    4: current pregnancy complicated by major fetal malformations or chromosomal abnormalities

    5: history or current diagnosis of preeclampsia, placental abruption, or placenta previa History of to intravenous iron therapy or iron overload disorders

    6: receipt of blood transfusion or intravenous iron therapy within 1 month before enrollment Psychiatric disorders or cognitive impairment that would interfere with study participation or compliance with study procedures

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    Preconception Group

    Townships assigned to this group implement anemia screening and indicated iron treatment before conception.

    Other: Preconception Anemia Screening and Treatment Strategy

  • Active comparator
    Early-Pregnancy Group

    Townships assigned to this group implement the same anemia screening and indicated iron treatment during early pregnancy.

    Other: Early-Pregnancy Anemia Screening and Treatment Strategy

Interventions

  • OtherPreconception Anemia Screening and Treatment Strategy

    Women planning pregnancy within 6 months undergo hemoglobin, hemoglobin electrophoresis, and serum ferritin assessments before conception. Those with hemoglobin levels below 120 g/L and/or serum ferritin levels below 30 μg/L receive oral ferrous succinate (0.2 g twice daily) plus vitamin C, with scheduled hematologic monitoring.

  • OtherEarly-Pregnancy Anemia Screening and Treatment Strategy

    Women with a singleton pregnancy at 12 weeks' gestation who have hemoglobin levels below 110 g/L and/or serum ferritin levels below 30 μg/L will receive oral ferrous succinate (0.2 g twice daily) plus vitamin C, with scheduled hematologic monitoring

06

What researchers measure

Primary outcomes

  1. Proportion of participants with iron deficiency anemia during late pregnancy

    Iron deficiency anemia is defined as a hemoglobin concentration of less than 110 g/L and a serum ferritin concentration of less than 20 μg/L, measured in the same blood sample. Participants meeting both criteria at least once during any scheduled assessment from 28 weeks' gestation through delivery will be classified as having the primary outcome.

    Time frame: From 28 weeks' gestation to delivery

07

Study locations

1 of 1 sites recruiting
  • Yanjin County Maternal and Child Health Hospital
    Zhaotong, Yunnan 657500, China
    Recruiting
    • Guimin Huang Huang · Contact394128854@qq.com · 13608704462
    • Peipei Hu Hu · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07811765
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Jul 10, 2026
Primary completion
Apr 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Sep 17, 2026

Study contacts

Peipei Hu
Contact
hupphpp@163.com
+86-21-25076143

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion